Buy LIZTOX® 100u Online

Product Description

LIZTOX™ (Clostridium Botulinum Toxin Type A) Injection Product Overview

LIZTOX™ is an injectable botulinum toxin type A product developed by Huons Biopharma for the temporary treatment of moderate to severe wrinkles, including glabellar lines (frown lines) and crow’s feet (lateral canthal lines). The product, designed for aesthetic and therapeutic use, utilizes botulinum toxin’s neuromodulatory effects to relax targeted facial muscles, providing smoother skin with fewer visible wrinkles. Available in 100 units per vial, LIZTOX™ is stored as a lyophilized powder and reconstituted with saline before administration.

Key Features:

• Active Ingredient: Botulinum toxin type A, 100 units per vial
• Applications: Moderate to severe glabellar lines and crow’s feet
• Form: Lyophilized powder to be reconstituted with saline for injection

LIZTOX™ Indications for Use

LIZTOX™ is approved for aesthetic purposes, specifically for temporarily reducing frown lines between the eyebrows and crow’s feet around the eyes. It is indicated for adult patients aged 19 to 65 years.

Primary Indications:

• Glabellar Lines: Reduces frown lines caused by corrugator and procerus muscle activity.
• Crow’s Feet: Minimizes lateral canthal lines through orbicularis oculi muscle relaxation.

LIZTOX™ Dosage Information

Dosage varies based on the treated area. For effectiveness, proper dilution and administration technique are crucial to achieving optimal, natural results.

Recommended Dosages and Techniques:

• Glabellar Lines: Dilute to 100 U/2.5 mL with preservative-free saline (4 U/0.1 mL). Inject 0.1 mL per site across five injection points (two per corrugator muscle and one in the procerus muscle), totaling 20 units.
• Crow’s Feet: Dilute similarly and inject 0.1 mL (4 U) into three sites along the outer orbicularis oculi muscle per side, totaling 24 units (12 units per eye).
• Dilution Procedure: Use sterile saline to reconstitute the product, avoiding excessive agitation. Record the reconstitution date and store the product at 2-8°C if not used immediately. Administer within 24 hours of dilution.

Expected Duration: Results typically last 3-4 months, depending on patient metabolism and dosage.

LIZTOX™ Side Effects and Precautions

LIZTOX™ is generally safe when used as directed, though patients may experience minor side effects related to the injection process. Patients with specific contraindications should avoid botulinum toxin products.

Common Side Effects:

• Localized Pain and Swelling: Temporary pain, redness, or swelling at the injection site, usually subsiding within 24-48 hours.
• Bruising and Tenderness: Mild bruising, especially in sensitive areas.
• Headache: Reported in some cases following facial treatments.

Warnings and Contraindications:

• Potential Spread of Toxin Effects: Botulinum toxin may spread beyond the injection site, leading to symptoms like muscle weakness, dysphagia, or breathing difficulties in rare cases.
• Hypersensitivity Risks: Patients with hypersensitivity to any component should not use LIZTOX™.
• Avoid in Neuromuscular Disorders: Individuals with disorders like myasthenia gravis or Eaton-Lambert syndrome are at higher risk of adverse effects.
• Pregnancy and Lactation: Not recommended due to limited safety data.

Precautionary Measures:

• Infection Control: Use aseptic technique to avoid infections.
• Proper Administration Training: Only trained professionals should administer the injections to reduce the risk of adverse events and toxin spread.

LIZTOX™ Clinical Studies or Real-World Outcomes

LIZTOX™ has shown efficacy and safety in multiple clinical studies, particularly in treating glabellar lines and crow’s feet.

Study Findings:

• Efficacy in Glabellar Lines: In a study with 267 participants, the response rate was 90.15% at four weeks, showing non-inferiority to control groups.
• Efficacy in Crow’s Feet: In another study with 290 participants, a 72.14% improvement was observed at four weeks, with comparable results between test and control groups.
• Duration of Effect: Most patients experience results lasting up to 16 weeks post-injection.

Patient Satisfaction and Adverse Event Rates:

• Satisfaction Levels: High satisfaction with wrinkle reduction and overall aesthetic results.
• Adverse Event Incidence: Mild side effects reported, with nasopharyngitis (6.21%) and injection site bruising (2.07%) being the most common.

LIZTOX™ Composition and Active Ingredients

LIZTOX™ consists of botulinum toxin type A, alongside stabilizing agents such as sodium chloride and albumin to maintain efficacy and reduce allergic reactions.

Key Components:

• Botulinum Toxin Type A: 100 units, with consistent potency for predictable results.
• Additives: Sodium chloride and albumin ensure stability and reduce hypersensitivity risks.

LIZTOX™ Drug Interactions

Due to its mechanism, LIZTOX™ may interact with specific medications, potentially increasing the risk of adverse effects.

Notable Interactions:

• Aminoglycosides: May amplify botulinum toxin’s effects, potentially increasing muscle weakness.
• Other Muscle Relaxants: Enhanced muscle relaxation effect with tubocurarine chloride, polymyxin B, or lincosamide antibiotics.
• Concurrent Botulinum Toxin Use: Avoid using other botulinum toxins within a few months to prevent excessive neuromuscular weakness.

Considerations for Anticholinergics: Patients using anticholinergic drugs may experience amplified systemic anticholinergic effects when combined with LIZTOX™.